Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma

• DOI: 10.4161/cbt.11.5.14669
• Publication Date: 2011-03-02T16:58:16Z
• Authors: Pei Zhou; Ping Liang; Baowei Dong; Xiaoling Yu; Zhiyu Han; Yingxin Xu
• Keywords: Cytokine-induced killer cell; CTL*

Background and Aims: To observe safety influence on viral load peripheral T lymphocyte subsets of combination therapy with percutaneous microwave ablation (PMWA) adoptive immunotherapy in hepatocellular carcinoma (HCC) hepatitis B. Methods: Ten HCC (D≤5 cm, fewer than 3 tumors) patients were treated radical PMWA three courses immunotherapy, which started PMWA, 2 weeks post-PMWA, months after PMWA. Peripheral blood mononuclear cells differentiated into phenotypically confirmed DCs effector cells. Immature DCs, cytokine-induced killer (CIK) cytotoxic lymphocytes (CTL) injected the marginal area ablated tumors under contrast-enhanced sonographic guidance. Under guidance, tumor lysate-pulsed DC was groin lymph nodes, while DC-CIK CTL abdominal cavity. CIK infused intravenously. Results: No adverse effects grade Ⅲ/Ⅳ observed. Viral decreased 57.14% (four seven) undetectable two (28.6%) without antiviral therapy. The percentage CD4+CD25high regulatory significantly, CD8+CD28- increased significantly 1 month However, 6 therapy, there no significant difference. Conclusion: Adoptive prescribed soon for safe ameliorated lymphocytes. See commentary: New prospects therapy: Microwave working together cellular